Skip to main content
. 2022 Jun 23;13:921253. doi: 10.3389/fimmu.2022.921253

Table 1.

Characteristics of patients.

Diagnosis Mutation Disease activity CRP (mg/dL) SAA (mg/L) Treatment
1 FMF M694V/M694V Mild 1,82 145 Colchicine
2 FMF M694V/V726A Almost absent 1,16 26 Colchicine
3 FMF M694V/V726A None <0,46 15,3 None
4 FMF M680I/V726A None <0,46 14,2 Colchicine
5 FMF M694V/M694V None <0,46 4,2 Colchicine
6 TRAPS C55Y None <0,46 2,07 Canakinumab
7 TRAPS C88Y None <0,46 1,8 Canakinumab
8 TRAPS C52Y None <0,46 5,39 Canakinumab
9 TRAPS T50M None <0,46 9,94 Canakinumab
10 TRAPS C55Y None <0,46 3,86 Canakinumab
11 MKD L265R/V377I None <0,46 4,1 Canakinumab
12 MKD C605insG/V377I Mild 1,21 135 Canakinumab
13 MKD C785_790delC/V377I None <0,46 7,2 Canakinumab
14 MKD V310M/V377I Moderate 3,08 130 None
15 MKD V377I/V377I None <0,46 16,8 None

FMF, familial Mediterranean fever; TRAPS, TNF receptor-associated periodic syndrome; MKD, mevalonate kinase deficiency; CPR, C-reactive protein; SAA, serum amyloid A.